


United States Patent & Trademark Office  
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

Scanned copy is best available.

Drawing most all fig are  
very dark

[REDACTED]

Case	Age	Sex	Duration	Site	Histology	Immunohistochemistry	Molecular biology	Prognosis	Treatment	Outcome	Follow-up	Comments
1	45	F	10 years	Rectum	Adenocarcinoma	CK20+, CK7+	HER2/neu+	Good	Chemotherapy	Alive	10 years	HER2/neu positive
2	60	M	5 years	Colon	Adenocarcinoma	CK20+, CK7+	HER2/neu-	Poor	Chemotherapy	Deceased	5 years	HER2/neu negative
3	55	F	8 years	Rectum	Adenocarcinoma	CK20+, CK7+	HER2/neu+	Good	Chemotherapy	Alive	8 years	HER2/neu positive
4	70	M	3 years	Colon	Adenocarcinoma	CK20+, CK7+	HER2/neu-	Poor	Chemotherapy	Deceased	3 years	HER2/neu negative
5	40	F	12 years	Rectum	Adenocarcinoma	CK20+, CK7+	HER2/neu+	Good	Chemotherapy	Alive	12 years	HER2/neu positive
6	65	M	7 years	Colon	Adenocarcinoma	CK20+, CK7+	HER2/neu-	Poor	Chemotherapy	Deceased	7 years	HER2/neu negative
7	50	F	9 years	Rectum	Adenocarcinoma	CK20+, CK7+	HER2/neu+	Good	Chemotherapy	Alive	9 years	HER2/neu positive
8	75	M	4 years	Colon	Adenocarcinoma	CK20+, CK7+	HER2/neu-	Poor	Chemotherapy	Deceased	4 years	HER2/neu negative
9	48	F	11 years	Rectum	Adenocarcinoma	CK20+, CK7+	HER2/neu+	Good	Chemotherapy	Alive	11 years	HER2/neu positive
10	62	M	6 years	Colon	Adenocarcinoma	CK20+, CK7+	HER2/neu-	Poor	Chemotherapy	Deceased	6 years	HER2/neu negative

Level -1  
Version 1.1  
Updated - 8/01/01